Drug Trial Radar · NCT03839875
Evaluation of Efficacy and Safety of Gynomax® XL Ovule
Last checked: Nov 20, 2026Latest source record: Jan 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Apr 3, 2019
Primary completion
Aug 9, 2019
Study completion Aug 9, 2019
Sponsor
- Lead sponsor
- Exeltis TurkeyIndustry
- Sponsor type
- Industry
- Collaborators
- Monitor CRO
- First posted
- Feb 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy and safety of Gynomax® XL ovule in the treatment of trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis and mixed vaginal infections will be evaluated in this open label, single-arm, multicentral study.
Conditions
- Trichomonal Vaginitis
- Bacterial Vaginosis
- Candidal Vulvovaginitis
- Mixed Vaginal Infections
Interventions
Gynomax® XL Vaginal OvuleDrug
tioconazole, tinidazole, lidocaine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with complete response to treatmentTime frame: 10 Days after completion of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ege University Family Planning and Infertility Application and Research Centeraştırma Merkezi
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.